Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q2 2026 ▲▼ | Q3 2026 ▲▼ | Change ▲▼ | Q2 2026 ▲▼ | Q3 2026 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Pyxis Oncology Inc | 0 | 15,541,909 | +15,541,909 | $0 | $36.21M | 21.75% | +$36.21M |
| Kyverna Therapeutics Inc | 0 | 4,521,318 | +4,521,318 | $0 | $30.74M | 18.47% | +$30.74M |
| Teva Pharmaceutical Inds LtdSHS | 0 | 379,520 | +379,520 | $0 | $15.03M | 9.03% | +$15.03M |
| Celldex Therapeutics, Inc.(CLDX) | 0 | 279,720 | +279,720 | $0 | $9.07M | 5.45% | +$9.07M |
| Tango Therapeutics, Inc.(TNGX) | 0 | 1,852,495 | +1,852,495 | $0 | $9.02M | 5.42% | +$9.02M |
| Vir Biotechnology, Inc.(VIR) | 0 | 803,552 | +803,552 | $0 | $8.98M | 5.40% | +$8.98M |
| Adarx Pharmaceuticals Inc | 0 | 450,000 | +450,000 | $0 | $8.97M | 5.39% | +$8.97M |
| Allogene Therapeutics Inc | 0 | 5,298,000 | +5,298,000 | $0 | $8.48M | 5.09% | +$8.48M |
| Bausch Plus Lomb Corp | 0 | 475,472 | +475,472 | $0 | $8.08M | 4.86% | +$8.08M |
| Editas Medicine Inc | 0 | 3,127,000 | +3,127,000 | $0 | $8.04M | 4.83% | +$8.04M |
| Incyte Corporation(INCY) | 0 | 51,080 | +51,080 | $0 | $6.20M | 3.72% | +$6.20M |
| Taysha Gene Therapies, Inc.(TSHA) | 0 | 248,000 | +248,000 | $0 | $6.19M | 3.72% | +$6.19M |
| Amgen Inc.(AMGN) | 0 | 14,512 | +14,512 | $0 | $6.12M | 3.67% | +$6.12M |
| Scholar Rock Holding Corporation(SRRK) | 0 | 110,500 | +110,500 | $0 | $5.34M | 3.21% | +$5.34M |